An interview with Aleksandra Wilk, director of the Lung Cancer Section, TO SIĘ LECZY Foundation.
Molecular diagnostics dramatically improve chances of lung cancer patients
Published June 21, 2023 12:21
Aleksandra Wilk:
- Molecular diagnostics are essential before starting treatment for lung cancer.
- With molecular diagnostics, mutations can be detected, the presence of which allows the use of targeted therapy.
- Thanks to innovative therapies, the treatment of lung cancer has changed a lot. The cancer has become a disease that can be treated chronically - with targeted immunotherapy. Patients enjoy long-term clinical benefit.
- We already have quite a few therapies in the B.6 drug program. However, there are still unmet needs.
- With early detection of lung cancer, patients can be treated radically with the intention of a complete cure.
- This is where the novelties come in - the first therapy registered in the U.S. and Europe, we hope will soon be reimbursed in Poland - immunotherapy after lung resection and after chemotherapy administration in patients who have PD-L1 protein expression above 50 percent. That's about 300 patients a year, a huge opportunity for them.
It's worth reading
